Article
[Second hematologic response and disappearance of the ABL gene mutant clone by cessation of imatinib in a CML patient with resistance to imatinib].
[Rinsho ketsueki] The Japanese journal of clinical hematology - 1 Sept 2004
Murase Kazuyuki, Matsunaga Takuya, Takeuchi Naoko, Fujimi Akihito, Takimoto Rishu, Terui Takeshi, Hirayama Yasuo, Niitsu Yoshiro
Abstract excerpt
A seventy-six year old female patient with chronic myelogenous leukemia (CML), (chronic phase), was treated with imatinib and obtained a major cytogenetic response after 6 months of treatment. However, resistance to imatinib appeared 9 months later due to an ABL gene point mutation, and the patient's platelet count and BCR/ABL positive rate had remarkably increased. We discontinued imatinib and used IFNalpha or...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.